输血相关急性肺损伤潜在治疗靶点的研究进展  

Advances in potential therapeutic targets for transfusion-related acute lung injury

作　　者：何芮 尹湧华[1] 王珏[1] 李玲[1] 刘忠[1] HE Rui;YIN Yonghua;WANGJue;LI Ling;LIU Zhong(Key Laboratory of Transfusion Adverse Reactions,Institute of Blood Transfusion,Chinese Academy of Medical Sciences and Peking Union Medical College,Chengdu 610052,China.)

机构地区：[1]中国医学科学院,北京协和医学院,输血研究所,输血不良反应研究重点实验室,四川成都610052

出　　处：《中国输血杂志》2020年第8期855-858,共4页Chinese Journal of Blood Transfusion

基　　金：中国医学科学院医学与健康科技创新工程(2016-I2M-3-024;2017-I2M-1-009);中国医学科学院中央级公益性科研院所基本科研业务费专项资金(2018PT32016)

摘　　要：输血相关急性肺损伤(TRALI)是输血相关的严重不良反应,是大多数国家输血相关死亡的主要原因之一,目前尚无特异性治疗方法。近10年,TRALI的病理生理学机制已逐渐阐明,许多研究从其发病机制的角度,深入探索TRALI的预防策略。本文主要对TRALI的发生机制及其潜在治疗措施进行临床前的评估和讨论,为其干预和治疗研究提供新的思路。Transfusion-related acute lung injury(TRALI), known as a serious adverse reaction developed during blood transfusion, is one of the leading causes of transfusion-related death around the world. There is, however, no specific clinical therapy currently. Recently, the pathophysiological mechanism of TRALI has been gradually clarified, and many literature have explored the prevention strategies of TRALI from the perspective of its pathogenesis. This article mainly focuses on the preclinical evaluation and discussion of the mechanism of TRALI and its potential treatment measures, so as to shed light on the regarding intervention and treatment.

关 键 词：输血相关急性肺损伤 干预 治疗 

分 类 号：R457.1[医药卫生—治疗学]